San Diego, California — According to state and local economic development sources Neurocrine Biosciences plans to invest $2,351,818.00 to build out new space in San Diego. The company plans to occupy the new space at 12780 El Camino Real in San Diego, on or about February 1, 2021. According to the company website Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids, with three pivotal and five mid-stage clinical programs in multiple therapeutic areas. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.

To learn more about Neurocrine Biosciences, visit http://www.neurocrine.com/

Company Contact:
Kevin Gorman, Chief Executive Officer
https://www.linkedin.com/in/kevin-gorman-4266076/
858-617-7600

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved